Hepatocellular Carcinoma Clinical Trial
Official title:
Biliary and Intestinal Microbiota Study in Liver Transplanted Patients
Many studies describe the relationship between microbiota alteration and the occurrence of
metabolic, alcoholic or inflammatory liver diseases. Nevertheless, the modifications of
microbiota during liver transplantation (LT) as well as its implication are poorly studied.
Similarly, only the intestinal microbiota is studied in this context, and no data are
available on the biliary microbiota, even if it is known that bile microbiota can interfere
with hepatobiliary diseases.
This study proposes a clinical and biological in-depth follow-up with multiple sampling of
liver transplanted patients to study biliary and intestinal microbiota alterations along LT,
as well as bile acids metabolism in corresponding fluids.
Indeed, in recipient samples as saliva, blood, urine, and feces can be taken before LT, and
surgeons can easily perform bile sampling during LT. In donors all samples can be taken
during liver removal. This offers the opportunity to have a microbiotic landscape of
individuals without liver disease (donor), and patients suffering from a chronic liver
disease or a liver cancer before and after transplantation.
Also, in Grenoble University hospital, in case of biliary anastomotic incongruence, a biliary
stent is placed during LT in 60% of recipients. This stent is removed by endoscopic
retrograde cholangiopancreatography (ERCP) within 6 months after LT, offering a second
opportunity to obtain bile samples in transplanted patients, after the early post-LT period.
Patients who do not require a biliary stent will also be included for the study of secondary
objectives, as intestinal microbiota is very poorly characterized in liver transplanted
patients too. A portion of the patients without biliary stent, may also develop an
anastomotic biliary stricture requiring an ERCP. If this ERCP is realized within the
follow-up period of the study, the patient will also be included in the primary objective of
the study.
These multiple and sequential samples will allow a complete analysis of microbiota changes in
LT patients and aim to answer to 3 questions:
1. What are the modifications of intestinal and biliary microbiomes during LT?
2. What is the influence of bile acids' composition on intestinal and biliary microbiota?
3. What are the relationships between microbiome alterations and the emergence of LT
complications?
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |